Table 1_Development and validation of an m6A and autophagy related lncRNAs signature for p

A prognostic risk model based on five m6A- and autophagy-related long non-coding RNAs (LINC00847, UBL7-AS1, LINC01554, LINC00601, FAM222A-AS1) for esophageal squamous cell carcinoma (ESCC). The model was developed using transcriptomic data from The Cancer Genome Atlas (TCGA) and validated with independent data from the Gene Expression Omnibus (GEO). It was created by Mingyi Yang and last updated in May 2026.

Use Cases

• Predicting overall survival in ESCC patients based on the five-lncRNA signature.
• Analyzing the association between risk scores and clinical features of ESCC.
• Investigating the tumor immune microenvironment, including immune cell infiltration and checkpoint molecule expression.
• Identifying potential therapeutic compounds tailored to distinct risk subgroups via drug sensitivity profiling.

Strengths

• The model is based on five specific lncRNAs (LINC00847, UBL7-AS1, LINC01554, LINC00601, FAM222A-AS1) identified through differential expression and co-expression analysis.
• Validation was performed using an independent cohort from the Gene Expression Omnibus (GEO).
• Analysis includes multiple validation methods: survival analysis, ROC curves, and single-cell sequencing data.

Limitations

• The dataset is a 37.6 KB DOCX file, suggesting limited raw data and likely containing summarized results or a manuscript.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for direct machine learning applications.

Provenance

Source

Transcriptomic data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).

Collection Method

Differential expression and co-expression analysis, followed by univariate Cox and LASSO regression to construct the prognostic signature.

Freshness

Last updated 2026-05-28 06:20:38; freshness should be verified.